Australian RSV immunisation update - new funded programs for infant protection

From early 2025, infants across Australia will benefit from new respiratory syncytial virus (RSV) protection programs, including a nationally-funded vaccination program for pregnant women, and state-and territory-funded long-acting monoclonal antibody programs for infants.

This NCIRS webinar will explore RSV disease and prevention and expand on the new funded RSV programs. Our panel of leading experts will present on:

• RSV disease in infants and young children
• effectiveness and safety of RSV vaccination and long-acting monoclonal antibody
• the new NIP-funded RSV vaccination program for pregnant women to protect their infants
• complementary state- and territory-funded RSV long-acting monoclonal antibody programs
• RSV prevention program resources to support healthcare providers.

A live Q&A session will follow the presentations and audience participation is encouraged.

The event will be recorded and made available on the NCIRS website in the days following the webinar.

Register to receive the link to the recording via email when it becomes available.